SWITZERLAND- The World Health Organization (WHO) has released two monoclonal antibodies as one of its top recommendations as part of its first Ebola virus disease treatment guidelines.
The recommendation comes as a result of an examination and analysis of clinical trials for the monoclonal antibodies mAb114 (also known as Ansuvimab or Ebanga) and REGN-EB3 (also known as Inmazeb).
The two antibodies have shown to have obvious advantages for those who have tested positive for the often-fatal Ebola virus.
This includes older people, women who are pregnant or nursing, children, and babies whose mothers were diagnosed with Ebola during the first week after giving birth.
Clinical trials were carried out while there were Ebola outbreaks with the largest experiment conducted in the Democratic Republic of the Congo, according to WHO.
The health body notes that the trial is proof that even during Ebola epidemics in challenging environments, the highest level of scientific rigor can be implemented.
The UN body also offered advice on medications like ZMapp and remdesivir that shouldn’t be used as therapies. It urges everyone to improve access to these life-saving medications.
The new recommendations, which were released simultaneously in English and French, will aid in the care of Ebola patients as well as the preparation and response of policymakers.
WHO was able to provide solid recommendations for the use of two treatments, but more study and evaluation of clinical interventions are required because there are still a lot of unknowns.
According to WHO, patients should receive recommended neutralizing monoclonal antibodies as soon as possible after laboratory confirmation of diagnosis.
Dr. Richard Kojan, co-chair of the Guideline Development Group of experts chosen by WHO, and president of ALIMA, The Alliance for International Medical Action, declared that this therapeutic guide was a crucial weapon in the fight against Ebola.
He continued that it will reassure the public, healthcare professionals, and patients that this fatal illness is treatable with potent medications.
Going forward, anyone who contract the Ebola virus will have a better chance of recovering if they seek medical attention as soon as they can.
Timeliness is crucial, just as with other infectious diseases, so patients should speak with medical professionals right away to guarantee they get the finest care.
WHO was able to provide solid recommendations for the use of two treatments, but more study and evaluation of clinical interventions are required because there are still a lot of unknowns.
Liked this article? Sign up to receive our regular email newsletters, focused on Africa and World’s healthcare industry, directly into your inbox. SUBSCRIBE HERE
